Daratumumab and antineoplastic therapy versus antineoplastic therapy only for people with newly diagnosed multiple myeloma ineligible for transplant
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Daratumumab and Antineoplastic Therapy Versus Antineoplastic Therapy Only for People With Newly Diagnosed Multiple Myeloma Ineligible for Transplant." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/436447/all/images/. Accessed 21 May 2024.
Daratumumab and antineoplastic therapy versus antineoplastic therapy only for people with newly diagnosed multiple myeloma ineligible for transplant. Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/436447/all/images/. Accessed May 21, 2024.
Daratumumab and antineoplastic therapy versus antineoplastic therapy only for people with newly diagnosed multiple myeloma ineligible for transplant. In Cochrane Abstracts https://evidence.unboundmedicine.com/evidence/view/Cochrane/436447/all/images/
Daratumumab and Antineoplastic Therapy Versus Antineoplastic Therapy Only for People With Newly Diagnosed Multiple Myeloma Ineligible for Transplant [Internet]. In: Cochrane Abstracts. [cited 2024 May 21]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/436447/all/images/.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Daratumumab and antineoplastic therapy versus antineoplastic therapy only for people with newly diagnosed multiple myeloma ineligible for transplant
ID - 436447
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/436447/all/images/
DB - Evidence Central
DP - Unbound Medicine
ER -